EGFR inhibitors plus dabrafenib and trametinib in patients with EGFR-mutant lung cancer and resistance mediated by BRAFV600E mutation: a multi-center real-world experience in China

作者：Wenyue Yang, Xiangran Feng, Jian Ni, Xinming Zhang, Hui Yu, Xianghua Wu, Huijie Wang, Xinmin Zhao, Zhihuang Hu, Bo Yu, Yao Zhang, Ying Lin, Yi Xiang, Jialei Wang · 发表于：Translational Lung Cancer Research · 年份：2024 · DOI：10.21037/tlcr-24-803 · 被引用次数：2 · 研究领域：Lung Cancer Treatments and Mutations、Melanoma and MAPK Pathways、Radiomics and Machine Learning in Medical Imaging

Background: The combination therapy of the B-Raf proto-oncogene (BRAF) inhibitor dabrafenib and the mitogen-activated protein kinase kinase (MEK) inhibitor Trametinib has shown favorable outcomes in patients initially identified with BRAFV600E mutations. However, there are currently no large-scale study data focusing on the use of a triple therapy regimen of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) plus dabrafenib and trametinib in patients with newly concomitant BRAF mutations after acquiring resistance to EGFR-TKIs. Our study aimed to explore the efficacy and safety of the triple therapy regimen through a multi-center real-world experience. Methods: We reviewed the medical records of 1,861 patients who were treated with EGFR-TKI targeted drugs at three major medical centers in Shanghai between June 2015 and August 2024. Among 1,288 patients who developed disease progression, we identified 14 patients who were treated with a triple therapy regimen of EGFR-TKI plus dabrafenib and trametinib due to newly acquired BRAFV600E mutation after EGFR-TKI resistance. The assessments comprised progression-free survival (PFS), overall survival (OS), objective response rate (ORR), disease control rate (DCR), and adverse events (AEs). We also performed further subgroup analysis to aid in identifying potential factors that influence treatment outcomes and enhance clinical decision-making. Results: At the time of the data cutoff (August 1, 2024), the estimated me...